We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

As Medicare announced a fresh set of drugs selected for its price-setting process on Friday under the Inflation Reduction Act ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Rhythm ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...

Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain.